Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stanford researchers uncover mystery behind how skull plates fuse

10.04.2003


Stanford University Medical Center researchers have identified a protein responsible for ensuring correct skull growth in newborn mice. The protein, called Noggin, inhibits fusion of bony plates in the skull until developmentally appropriate. The scientists hope that Noggin may one day replace surgery as a way to treat premature skull fusion in infants.



"About 1 in 2,000 children has growth plates in their skull that fuse prematurely," said Michael Longaker, MD. "The brain is rapidly expanding in size during the first two years of life. If the brain’s container - the skull - can’t expand in a similar fashion, you have a big problem." Left untreated, the condition can lead to mental retardation, blindness and seizures, as well as a severely misshapen head.

Longaker, a pediatric craniofacial surgeon at Lucile Packard Children’s Hospital and a professor of surgery at the School of Medicine, can correct the defect by removing sections of fused bone from an infant’s skull. But the operation is complex. And because it’s difficult to accurately predict how much room is needed for expansion, the procedure may need to be repeated as the brain grows.


At first, Longaker and his colleagues suspected that the root of the problem was the inappropriate expression of proteins that stimulate bone growth in the skull. They began comparing when and where these proteins were produced, but they started on the wrong track.

"It’s not as simple as promoting bone induction," said Longaker, the principal investigator of the research, which is published in the April 10 issue of Nature. "It turns out that the inhibitors are equally important. We had been missing the point."

The researchers discovered that the bone-promoting proteins are present between all the skull growth plates in mice: those that are actively fusing and those that are not. In contrast, Noggin, a known inhibitor of bone formation, was found only between plates that remained open. The scientists began to suspect that, like a testy chaperone at a high school dance, Noggin keeps the two edges of the skull apart. And like anxious teenagers, the bones reach out to each other when Noggin is removed from the mix.

Noggin’s new role in skull fusion was confirmed dramatically when the scientists injected a Noggin-producing virus between the bone plates along mice foreheads. The plates, which normally would have fused, remained open. This resulted in the animals developing blunt muzzles and wide-set eyes.

Although the results were clear, there was another mystery to be solved. In a seemingly futile loop, the very bone-promoting protein required for fusion also induced Noggin production. Then the researchers found that over-expression of another protein, called FGF2, inhibited Noggin expression in cell culture. The finding correlated with the fact that some human disorders characterized by premature skull fusion are caused by mutations in a receptor for FGF2 that kick the protein into overdrive. These mutants also turned off Noggin expression.

"We had been wondering how FGF2, which is involved in promoting new blood vessels, stimulated bone formation," said Longaker. "Now we know that it works, in part, by decreasing the amounts of inhibitors of bone formation."

The scientists are now working to understand how FGF2 decreases Noggin production, with an eye to a less-invasive treatment for infants with premature fusion. But such treatment would likely require early diagnosis of any problems.

"Can Noggin unlock an existing bone bridge? That would be a tall order," said Longaker. "But if premature fusion could be diagnosed before birth, a window of therapy could present itself." He envisions a day when sophisticated prenatal ultrasound or genetic testing could identify infants at risk before fusion began. By injecting Noggin-producing cells or viruses into the breach between growth plates, physicians could stave off inappropriate fusion until the brain finished expanding.

"Unlike some gene therapy challenges, we wouldn’t need to express Noggin for the life of the child," said Longaker. "The first two years would be adequate." Such a treatment would represent a huge leap over existing therapy. "Craniofacial surgery is more of a chisel-and-saw approach," he added. "We’ve had technical improvements, but it hasn’t really evolved. This finding represents a biomolecular approach that may re-establish normal growth and appearance of the skull, which is the most important research outcome."

Longaker’s colleagues include Stephen Warren, MD, of Stanford; Lisa Brunet, PhD, and Richard Harland, PhD, of the University of California-Berkeley; and Aris Economides, PhD, of Regeneron Pharmaceuticals, Inc, in Tarrytown, NY. Noggin was first identified by Harland in 1992 as a protein that guides tissue fate in developing frog embryos.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. .For more information, please visit the Office of Communication & Public Affairs Web site at http://mednews.stanford.edu/ and the Lucile Packard Children’s Hospital Web site at http://www.lpch.org/.

Krista Conger | EurekAlert!
Further information:
http://med-www.stanford.edu/MedCenter/MedSchool/
http://www.lpch.org/

More articles from Life Sciences:

nachricht What the world's tiniest 'monster truck' reveals
23.08.2017 | American Chemical Society

nachricht Treating arthritis with algae
23.08.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>